Find Academic Supervisors

Thi Thanh Hue DinhView profile

Research Fellow

• Microbiology
• Immunology
• Antifungal Research
• +4 more

Dr. Thi Thanh Hue Dinh serves as a Postdoctoral Research Fellow at Macquarie University's School of Natural Sciences, where she conducts cutting-edge research in antimicrobial therapeutics and infectious disease mechanisms. Her work bridges pharmacology, microbiology, and drug discovery with particular focus on fungal pathogens and novel treatment strategies. Dr. Dinh's research program centers on antifungal drug development, utilizing both Galleria mellonella (wax moth) and Drosophila melanogaster (fruit fly) infection models to evaluate therapeutic efficacy. Her recent publications demonstrate expertise in purine analogues, synthetic peptides, cannabinoid derivatives, and combination therapies targeting Candida albicans and other fungal pathogens. She employs advanced techniques including molecular pathway analysis, drug synergy testing, and virulence factor characterization to overcome antimicrobial resistance. Analysis of her 2024-2025 publications reveals a strategic focus on translational research with strong clinical relevance. Her work spans multiple therapeutic approaches including novel compound synthesis, mechanism of action studies, and toxicity reduction strategies. The research consistently demonstrates interdisciplinary collaboration across microbiology, pharmacology, and medicinal chemistry with clear pathways to clinical application. Dr. Dinh currently leads as Chief Investigator on the active research project 'A peptide-based adjuvant therapy to reduce the toxicity of Amphotericin B treatment of invasive fungal infections' (2024-2025), collaborating with Professor Cain and other researchers across Macquarie University. Her publication record shows consistent productivity with 23 research outputs through 2025, including high-impact publications in Nature Communications, Cell Reports, and ACS Infectious Diseases.

• Airway Immunology
• Cystic Fibrosis Research
• Airway Epithelial Cell Biology
• +5 more

Kelly Martinovich serves as an Adjunct Research Fellow at the UWA Medical School and UWA Centre for Child Health Research, affiliated with The Kids Research Institute Australia at The University of Western Australia in Perth, Australia. Her research profile demonstrates extensive contributions to pediatric respiratory and immunological sciences. Dr. Martinovich's research expertise centers on airway immunology and microbiology with significant focus on cystic fibrosis, airway epithelial cell biology, asthma pathogenesis, Nontypeable Haemophilus Influenzae infections, and tight junction function. Her fingerprint analysis reveals dominant research themes including Airway Immunology and Microbiology (100%), Cystic Fibrosis (37%), and Airway Epithelial Cell research (36%). This work directly contributes to UN Sustainable Development Goals related to good health and well-being. Her recent publication record shows a strong trajectory in developing sophisticated animal models to investigate respiratory infection mechanisms, particularly examining virus-bacteria interactions in influenza and Haemophilus species. Notable research directions include novel cystic fibrosis therapeutic approaches using gene therapy and CFTR modulators, maternal antibody transfer mechanisms for infant protection, and preventive strategies against otitis media. These studies demonstrate translational potential for developing new clinical interventions. With 26 total research outputs including 21 articles, 3 abstracts, 1 review, and 1 doctoral thesis, Dr. Martinovich's work has accumulated 563 citations yielding an h-index of 12. Her research shows active international collaboration patterns across multiple countries as visualized in network analysis. Dr. Martinovich maintains active research collaborations with prominent investigators including Richmond, P.C., Kirkham, L.A.S., Kicic, A., Strickland, D.H., and Thornton, R.B. Her work bridges basic science with clinical applications through affiliation with The Kids Research Institute Australia, focusing on improving outcomes for children with respiratory conditions and infections.

Sudha SundarView profile

Professor

• Gynaecological Oncology
• Ovarian Cancer
• Cancer Diagnostics
• +9 more

Sudha Sundar is a Professor of Gynaecological Cancer in the Department of Cancer and Genomic Sciences at the University of Birmingham, where she serves as a clinical academic and gynaecological cancer surgeon. She is actively involved in national and international leadership, currently serving as the National Ovarian Cancer Audit Surgical Lead (2023–present) and a member of the International Advisory Board of Lancet Oncology (2025–). Previously, she was President of the British Gynaecological Cancer Society (2019–2022), the first woman gynaecological oncologist to hold this role. She also serves as India Lead for the College of Medicine and Health (2017–present) and Academic Lead for the Cancer Pillar at Birmingham Health Partners (2018–present). Research Interests: Her research program focuses on three core areas: improving cancer diagnostics, optimizing cancer surgery, and addressing inequalities in cancer outcomes. She leads clinical and translational research initiatives such as the ROCkeTS trial (diagnostic accuracy in ovarian cancer), the Global Equality in Ovarian Cancer Care Project (GEOCC), and studies on mucinous ovarian cancer (STEMOVA). Her work integrates clinical trials with genomic analysis and real-world data to drive policy change and improve patient outcomes. Publications and Research Trends: Her recent publications reflect a strong emphasis on ovarian cancer diagnostics, surgical outcomes, health disparities, and guideline development. She frequently publishes in high-impact journals like Nature Genetics , Lancet Oncology , Gynecologic Oncology , and BJOG . Her work often involves large-scale data analysis, systematic reviews, and clinical guidelines, demonstrating a translational and policy-oriented research approach. Scientific Leadership and Recognition: President, British Gynaecological Cancer Society (2019–2022) National Ovarian Cancer Audit Surgical Lead (2023–present) Co-Chair, International Gynaecological Cancer Society Conference Scientific Program Committee (2024) Member, International Advisory Board, Lancet Oncology (2025–) India Lead, College of Medicine and Health, University of Birmingham (2017–present) Academic Lead, Cancer Pillar, Birmingham Health Partners (2018–present) Lead, Ethnic Diversity in Cancer Genomics Substream, Institute of Global Innovation Teaching and Mentoring: Professor Sundar provides bedside and small group teaching for Year 4 and Year 5 medical students and serves as a personal academic tutor for Year 1 and Year 2 students. She welcomes MD and PhD trainees interested in gynaecological oncology research. Labs and Research Teams: She leads a multidisciplinary research team focused on gynaecological cancers, collaborating with institutions such as Imperial University and the Royal College of Obstetricians and Gynaecologists. Her work is supported by national audits, clinical trials (e.g., ROCkeTS), and international consortia like the International Gynaecological Cancer Society. She is deeply involved in using routinely collected health data to drive quality improvement and equity in cancer care.

• Antimicrobial Resistance
• Bacterial Infections
• Antibiotic Pharmacodynamics
• +3 more

Patrice Nordmann is a Full Professor in the Department of Medicine at the University of Fribourg, part of the Faculty of Mathematics, Natural Sciences and Medicine. His research focuses on antibiotic resistance mechanisms, particularly in Gram-negative bacteria, with an emphasis on beta-lactamase inhibitors, carbapenemase-producing pathogens, and novel antibiotic combinations. He leads studies on rapid diagnostic methods for antimicrobial susceptibility testing and investigates pharmacokinetic/pharmacodynamic interactions of last-resort antibiotics. His work bridges clinical microbiology, molecular biology, and therapeutic innovation to combat multidrug-resistant infections. Research interests include: antimicrobial resistance mechanisms, beta-lactamase enzymology, antibiotic susceptibility testing methodologies, and pharmacodynamic optimization of combination therapies. Recent studies explore resistance emergence to novel agents like cefiderocol, ceftazidime-avibactam, and meropenem-vaborbactam, as well as cross-resistance patterns in KPC, NDM, and OXA-producing strains. Key contributions involve developing rapid diagnostic tools such as the Rapid CAZ/AVI NP Test and evaluating synergistic antibiotic pairs against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. His studies also address epidemiological aspects like plasmid-mediated resistance in veterinary and human clinical settings. Notable collaborations include genomic analyses of Klebsiella pneumoniae and Acinetobacter baumannii isolates, and investigations into the role of porin modifications and efflux pumps in antibiotic resistance. His work frequently integrates in vitro time-kill models with clinical trial data to inform treatment regimens.

Hasindu Malshan GamaarachchiView profile

Lecturer

• Bioinformatics
• Genomics Data Processing
• Embedded Systems
• +3 more

Hasindu Malshan Gamaarachchi is a Lecturer in the School of Computer Science and Engineering at UNSW Sydney since 2023, and a visiting scientist at the Garvan Institute of Medical Research's Genomic Technologies Group. He completed his PhD in Computer Science and Engineering at UNSW Sydney (2020) and holds a BSc (Hons.) in Computer Engineering from the University of Peradeniya (2015). His research focuses on bioinformatics software and hardware systems for real-time nanopore sequencing analysis, embedded computing, and GPGPU/FPGA acceleration. Education: PhD in Computer Science and Engineering, UNSW Sydney (2020) BSc Engineering (Hons.) in Computer Engineering, University of Peradeniya (2015) Research Interests: Design and optimization of domain-specific systems for genomics, including nanopore sequencing analysis, algorithmic efficiency, and hardware-software co-design. Key applications include real-time data processing and embedded systems for bioinformatics. Grants & Awards: ARC Discovery Early Career Researcher Award (DECRA) 2023 (Sole CI) ARC Discovery Projects 2023 (CI with Sri Parameswaran) 2021: Outstanding PhD Thesis Award (ABACBS), Dean's Award (UNSW) 2020: Third place at ACM SRC Awards span academic excellence (e.g., IET-YPS 2016) to bioinformatics innovation. Collaborates with industry and institutions like Garvan for genomic technologies.

• Cardiology
• Electrophysiology
• Heart Rhythm Disorders
• +4 more

Gaetano Paparella is a Physician Scientist specializing in heart rhythm management and cardiovascular diseases at the Department of Cardiology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel. He maintains clinical practice at University Hospital Brussels (UZB) located at Laarbeeklaan 101, 1090 Jette, Belgium, with strong research integration into his clinical work. His primary research interests focus on cardiac electrophysiology, particularly atrial fibrillation and Brugada syndrome. His work spans diagnostic approaches, genetic testing implications, and innovative treatment strategies for cardiac arrhythmias. He has made significant contributions to understanding the relationship between genetic mutations and clinical manifestations in arrhythmia syndromes. Analysis of his 86 publications reveals consistent research focus on cardiac rhythm disorders, with particular emphasis on the application of advanced imaging techniques like speckle-tracking echocardiography and electrocardiographic imaging. His work demonstrates increasing collaboration with international research groups, particularly in genetic studies of arrhythmia syndromes. His research output shows steady productivity with 11 publications in 2021 and 2022, demonstrating ongoing active engagement in the field. The publication trend indicates growing focus on genetic aspects of arrhythmia syndromes alongside traditional electrophysiology research. Dr. Paparella maintains extensive collaborative relationships with leading European electrophysiologists including Pannone L., Sarkozy A., Brugada P., Chierchia G.B., and de Asmundis C., contributing to multicenter studies and registry-based research that has influenced clinical practice guidelines.

Diana HallView profile

Associate Professor

• Forensic Genetics
• Molecular Methods
• DNA Mixture Analysis
• +7 more

Diana Hall is an Associate Professor at the Faculty of Biology and Medicine, University of Lausanne (UNIL), and leads research at the Forensic Genetics Unit of the Romandie University Center for Forensic Medicine (CURML) since 2010. She also teaches at the UNIL School of Criminal Justice and was appointed to her current academic rank in 2024. Her research focuses on forensic genetics, particularly the development of molecular methods for analyzing complex and unbalanced DNA mixtures. Her pioneering work on DIP-STR markers has advanced forensic DNA profiling in criminal investigations, prenatal paternity testing, and transplant monitoring. She has conducted extensive research on individual ancestry inference using genetic markers as investigative leads. The recent publications highlight a consistent trend in the development and validation of DIP-STR technology for forensic applications, especially in cases involving trace DNA, touch samples, and high-ratio mixtures. These studies demonstrate both technical innovation and practical implementation in real forensic settings. Scientific Affiliations: Faculty of Biology and Medicine, University of Lausanne Romandie University Center for Forensic Medicine (CURML) UNIL School of Criminal Justice Research and Advising: Diana Hall leads a research group focused on novel molecular approaches in forensic genetics. She has not publicly listed any students, but her team has produced impactful research in forensic DNA analysis. Her work is supported by institutional affiliations rather than specific grant mentions in the text. She has contributed significantly to forensic science through methodological innovation. Laboratories and Teams: She is affiliated with the Forensic Genetics Unit at CURML, where her research integrates molecular biology, genetics, and forensic science to solve practical challenges in criminal justice and clinical monitoring.

Kathryn MeursView profile

Professor

• Genetics
• Spontaneous Animal Disease Models
• Cardiovascular Disease
• +3 more

Kathryn Meurs is the Randall B. Terry Jr. Dean of the College of Veterinary Medicine at North Carolina State University. A Diplomate of the American College of Veterinary Internal Medicine (Cardiology), she holds a Ph.D. in Genetics from Texas A&M University and completed her DVM at the University of Wisconsin–Madison followed by a cardiology residency at Texas A&M. Her research focuses on the genetics of cardiovascular diseases in animals, particularly familial cardiomyopathy . Dr. Meurs’ recent publications highlight her expertise in feline and canine cardiomyopathy , genetic mutation analysis , and cross-species disease modeling . Her work spans genetic research , clinical pharmacology , and veterinary education challenges , with a strong emphasis on spontaneous animal disease models for human conditions. She contributes to initiatives like the NC State Veterinary Medicine newsletter, early-career educator workshops, and innovative cancer care programs. While her scientific awards include board certification in veterinary cardiology , the text does not mention specific grants or student advising details.

• Pulmonary Fibrosis
• Metabolic Reprogramming
• Chronic Lung Diseases
• +9 more

Farida Ahangari, MD , is an Assistant Professor in the Department of Internal Medicine at Yale School of Medicine , with a primary affiliation in the Pulmonary, Critical Care & Sleep Medicine section. She is also associated with the Kaminski Lab and the Center for Precision Pulmonary Medicine (P2MED) , where she leads translational research on chronic lung diseases. Assistant Professor of Medicine (Pulmonary) Department of Internal Medicine, Yale School of Medicine Affiliated with Kaminski Lab and P2MED Education & Training: MD, Iran University of Medical Sciences (1995) Research Trainee, Queensland Institute of Medical Research (2002) Postdoctoral Associate, University at Buffalo (2006) Postdoctoral Fellow, Yale School of Medicine (2012) Research Interests: Dr. Ahangari's research focuses on the pathogenesis of pulmonary fibrosis, particularly the role of metabolic reprogramming and noncoding RNAs (e.g., microRNAs) in disease progression. Her work bridges molecular mechanisms with clinical translation, aiming to develop targeted, cell-specific therapies for idiopathic pulmonary fibrosis (IPF) and other chronic lung diseases. Publication Trends: Her recent publications emphasize single-cell genomics , epigenetic aging , in silico modeling , and drug discovery in fibrotic lung diseases. Key themes include GPR87 signaling, miR-205 regulation, mitochondrial DNA-TLR9 interactions, and ex vivo fibrosis models, reflecting a strong focus on precision medicine and systems biology. Scientific Awards: Blavatnik Fund for Innovation at Yale Advising and Grants: While no specific students are listed, Dr. Ahangari leads multicenter collaborative projects and mentors researchers within her lab. She has secured funding from competitive sources such as the Blavatnik Fund, supporting innovative research in pulmonary fibrosis. Her work is highly collaborative, involving frequent co-authorship with Naftali Kaminski, Taylor Adams, Johad Khoury, and others. Labs and Teams: Dr. Ahangari is an integral member of the Kaminski Lab , a leading research group in pulmonary genomics and fibrosis. She also contributes to the Center for Precision Pulmonary Medicine (P2MED) , which leverages advanced technologies to develop personalized treatments for lung diseases.

• Cytopathology
• Thyroid Cancer
• Head and Neck Neoplasms
• +5 more

Rita Abi-Raad, MD, is an Associate Professor in the Department of Pathology at Yale School of Medicine. She specializes in cytopathology with clinical focus on thyroid, head and neck, and gynecologic cancers. She is board certified in Anatomic & Clinical Pathology and Cytopathology and serves as Associate Residency Program Director in Pathology, contributing significantly to medical education and training. Education: MD, Saint Joseph University - School of Medicine, Lebanon (1994) Residency, Anatomic and Clinical Pathology, Yale-New Haven Hospital Fellowship, Cytopathology, Yale-New Haven Hospital Research Interests: Dr. Abi-Raad's research is centered on refining diagnostic methodologies in cytopathology, particularly through fine-needle aspiration and molecular testing. Her work investigates biomarker expression, tumor grading in neuroendocrine tumors, and the diagnostic utility of KRAS mutation analysis in gynecologic specimens. She emphasizes accuracy in cytologic interpretation and improving diagnostic sensitivity in challenging clinical scenarios. Publication Trends: Her recent publications (2013–2021) reflect a consistent focus on diagnostic pathology, with particular emphasis on thyroid, pancreatic, and gynecologic malignancies. The articles integrate cytologic evaluation with immunohistochemical and molecular techniques, showcasing a translational approach to improving cancer diagnostics. Professional Service: Associate Residency Program Director, Pathology Member, Papanicolaou Society of Cytopathology (2018–Present) Advising and Grants: While specific details on students or grant funding are not provided, her leadership role as Associate Residency Program Director indicates active mentorship and educational leadership. There is no mention of external grants, but her collaborative research suggests involvement in institutional or departmental research initiatives. Labs and Teams: Dr. Abi-Raad is affiliated with several programs at Yale, including Cytopathology, Gynecological Pathology, and the Pancreatic Diseases Program. She frequently collaborates with researchers such as Pei Hui, Natalia Buza, and Guoping Cai, indicating integration within interdisciplinary diagnostic and research teams.

• Biochemistry
• Molecular Biology
• Clinical Biochemistry
• +4 more

Davide Ferrari is an Associate Professor at the Department of Chemical, Life, and Environmental Sustainability Sciences at the University of Parma. His academic work spans biochemical-clinical analysis, molecular diagnostics, and virology-related research. Teaching appointments include courses in Pharmaceutical Chemistry, Clinical Biochemistry, and Molecular Biology for Medicine, Pharmacy, and Biotechnology programs. Research focuses on SARS-CoV-2 transmission mechanisms, viral immunology, and diagnostic testing optimization. Recent publications highlight his work on: Monkeypox cross-neutralization by smallpox vaccines Cell-to-cell transmission dynamics in SARS-CoV-2 variants Improving diagnostic efficiency through automated analyzers

Matthew GubensView profile

Professor

• Thoracic Medical Oncology
• Lung Cancer
• Mesothelioma
• +3 more

Matthew Gubens, MD, MS, FASCO is a Professor of Medicine at the University of California San Francisco (UCSF), specializing in thoracic medical oncology. He serves as Medical Director of Thoracic Medical Oncology and Chair of the UCSF Cancer Center Protocol Review and Monitoring Committee, overseeing clinical cancer research. Dr. Gubens is actively involved in guideline development as Immediate Past Chair of the ASCO Evidence Based Medicine Committee, co-chair of the ASCO Thoracic Guideline Advisory Group, and member of National Comprehensive Cancer Network panels for non-small cell lung cancer , mesothelioma , and thymic malignancies . He also contributes to the Association of Northern California Oncologists as a Board member. Education: BA in Ethics, Politics, and Economics from Yale University (1997) MS in Health Policy and Management from Harvard School of Public Health (2000) MD from Stanford University School of Medicine (2005) Internal Medicine Residency at UCSF School of Medicine (2008) Medical Oncology Fellowship at Stanford School of Medicine (2011) His research focuses on thoracic oncology , with significant contributions to lung cancer , mesothelioma , and thymic malignancies through clinical trials, guideline development, and biomarker studies. Recent publications address multidisciplinary cancer care, frailty assessment in older adults, and genetic predictors of immunotherapy toxicity. Dr. Gubens participates in several national committees and guideline panels, including NCCN and American Radium Society, focusing on optimizing treatment protocols and managing therapy-related complications.

• Cancer Epidemiology
• Biostatistics
• Genetic Variants
• +3 more

Colin B. Begg is a Professor of Biostatistics in the Population Health Sciences department at Weill Cornell Medical College. His research focuses on cancer epidemiology, genetic variant analysis, and clinical trial methodology. Key Research Areas: Melanoma survival genetics, tumor clonality testing, cancer risk prediction models, and clinical trial design optimization. Recent Contributions: Developed mutation context analysis frameworks, validated population-based clinical trial data sources, and advanced statistical methods for molecular epidemiology studies. Publication Trends: Recent articles emphasize biostatistical approaches to cancer genomics, including driver mutation identification in melanoma, vitamin D-binding protein variants in oncology, and improved variable selection techniques for clinical models. His work bridges computational methods with clinical application across oncology and epidemiology.

Barbara CampaniniView profile

Associate Professor

• Biochemistry
• Enzymology
• Antimicrobial Drug Discovery
• +4 more

Barbara Campanini is an Associate Professor of Biochemistry (SSD BIO/10) at the Department of Food and Drug Sciences, University of Parma, where she has held a full-time position since 2016. She obtained her honors degree in Medicinal Chemistry (1998) and PhD in Molecular Biology and Pathology (2002) from the University of Parma, with research conducted at the University of Oklahoma and University of Illinois at Urbana-Champaign. Research Focus: Her work centers on enzyme characterization, particularly pyridoxal 5'-phosphate-dependent enzymes in bacterial and human systems. Key areas include: Bacterial cysteine biosynthesis enzymes as antibiotic targets Heme capture mechanisms in Staphylococcus aureus Human PLP-dependent enzymes for drug development Metabolic pathways in neurological disorders Publications & Trends: Recent articles (2024-2025) demonstrate strong emphasis on antimicrobial strategies targeting bacterial iron acquisition, enzyme inhibition for neurological disorders, and structural analysis of protein interactions. Over 60 peer-reviewed papers reflect interdisciplinary approaches combining biochemistry, biophysics, and medicinal chemistry. Academic Roles: Supervised >30 Master/PhD students PhD program committees: Biochemistry & Molecular Biology (2006-2012), Drugs & Biomolecules (2013-present) Lecturer at international summer schools (ULLA, Paris Sud) Professional Service: Editorial Board member for Scientific Reports , Frontiers in Chemistry , and Frontiers in Molecular Biosciences since 2018; reviewer for major journals including Journal of Medicinal Chemistry . Laboratory: Conducts research at Biochemistry and Molecular Biology Laboratories, Parco Area delle Scienze 23/A, Parma.

Cornelia van DiepenView profile

Assistant Professor

• Person-Centered Care
• Healthcare Policy
• Nursing
• +3 more

Cornelia van Diepen serves as an Assistant Professor at the Erasmus School of Health Policy & Management, specializing in Socio-Medical Sciences. Her research focuses on person-centered care, healthcare workforce well-being, and psychosocial interventions in clinical settings. Person-Centered Care : Investigating its impact on staff stress and job satisfaction. Occupational Health : Developing tools like the Capacity to Work Index for mental health assessment. Qualitative Methodology : Studying pandemic effects on nursing home staff and BRCA-related care frameworks. Recent publications highlight collaborations across Europe, emphasizing stress reduction in hospital environments (2025) and validating healthcare metrics (2024). No awards, students, or lab details are explicitly mentioned in the provided profile.